Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

Clinical trial NCT07251582 · RECRUITING

Trial details

NCT number: NCT07251582
Sponsor: Hunan Province Tumor Hospital
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

Start date: 2026-08-12
Primary completion: 2028-10-31
Enrollment: 186

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.